2023. 1. 6, 코리아 바이오메디칼 리뷰

Commenting on whether this new platform could be beneficial for Korea’s vaccine manufacturing hubs, IVI’s Deputy Director Anh Wartel explained, “IVI is not currently involved in any project using the molecular clamp technology approach but is supporting vaccine manufacturers using various platforms like the inactivated, DNA, mRNA, protein-based adjuvanted, and adenoviral vectors to accelerate vaccine R&D against SARS-CoV-2 since February 2020 across preclinical, clinical as well as pre-and post-authorization studies,”

기사 보기 (영문)  >>